Controversies of Oral Antiplatelet Therapy in Acute Coronary Syndromes and Percutaneous Coronary Intervention

ABSTRACT

Platelet activation is a pivotal event in the pathophysiology of acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI) and has a substantial impact on the outcomes in these settings. Aggressive implementation of antiplatelet therapy has significantly decreased adverse cardiovascular events, such as death, myocardial infarction (MI), stroke, and repeat revascularization. Although the widespread use of aspirin has contributed to this improvement, many patients continue to have a significant risk of recurrent events during the ensuing months to years. The advent of other antiplatelet agents, notably the thienopyridine clopidogrel bisulfate has heralded a new era of combined antiplatelet blockade, offering the hope of better outcomes. Recently, clinical trials have tested the use of dual oral antiplatelet blockade and have shown impressive results. Notably, the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial found that dual therapy with clopidogrel and aspirin in ACS reduced adverse cardiovascular events by 20% at 1 year (p < 0.001). The PCI-CURE substudy of CURE and the Clopidogrel for the Reduction of Events During Observation (CREDO) trial demonstrated that these benefits extend to patients undergoing both urgent and elective PCI. This article will explore the current role of and controversies in oral antiplatelet therapy after ACS and PCI.

Aspirin - clopidogrel - acute coronary syndromes - percutaneous coronary intervention

REFERENCES

• 1 American Heart. Association .Heart and Stgroke Statistical Update. www.americanheart.org/presenter.jhtm/?identifier=1928. Accessed August 2003
• 2 Bhatt D L, Topol E J. Scientific and therapeutic advances in antiplatelet therapy.  Nat Rev Drug Discov. 2003;  2 15-28
• 3 Mehta S R, Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.  J Am Coll Cardiol. 2003;  41(4 Suppl S) 79S-88S
• 4 Ault K A, Cannon C P, Mitchell J et al.. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.  J Am Coll Cardiol. 1999;  33 634-639
• 5 Merlini P A, Bauer K A, Oltrona L et al.. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction.  Circulation. 1994;  90 61-68
• 6 Perretti M, Chiang N, La M et al.. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor.  Nat Med. 2002;  8 1296-1302
• 7 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 ( Second International Study of Infarct Survival) Collaborative Group.  Lancet. 1988;  2 349-360
• 8 Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
• 9 Gum P A, Kottke-Marchant K, Poggio E D et al.. Profile and prevalence of aspirin resistance in patients with cardiovascular disease.  Am J Cardiol. 2001;  88 230-235
• 10 Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease.  Thromb Res. 2002;  108 37-42
• 11 MacDonald T M, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin.  Lancet. 2003;  361 573-574
• 12 Catella-Lawson F, Reilly M P, Kapoor S C et al.. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.  N Engl J Med. 2001;  345 1809-1817
• 13 Hollopeter G, Jantzen H M, Vincent D et al.. Identification of the platelet ADP receptor targeted by antithrombotic drugs.  Nature. 2001;  409 202-207
• 14 Yusuf S, Zhao F, Mehta S R et al.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.  N Engl J Med. 2001;  345 494-502
• 15 Budaj A, Yusuf S, Mehta S R et al.. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups.  Circulation. 2002;  106 1622-1626
• 16 Yende S, Wunderink R G. Effect of clopidogrel on bleeding after coronary artery bypass surgery.  Crit Care Med. 2001;  29 2271-2275
• 17 Hongo R H, Ley J, Dick S E, Yee R R. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting.  J Am Coll Cardiol. 2002;  40 231-237
• 18 Bhatt D L, Topol E J. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.  JAMA. 2000;  284 1549-1558
• 19 Topol E J. A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes.  J Am Coll Cardiol. 2003;  41(4 Suppl S) 123-129
• 20 Lau W C, Waskell L A, Watkins P B et al.. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.  Circulation. 2003;  107 32-37
• 21 Serebruany V L, Steinhubl S R, Hennekens C H. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested.  Circulation. 2003;  107 1568-1569
• 22 Serebruany V L, Malinin A I, Steinhubl S R, Callahan K P, Gurbel P A. Statins in General and Atorvastatin in Particular Do Not Affect Platelet Inhibition with Clopidogrel During Coronary Stenting. Presented at the 52nd Annual American College of Cardiology Scientific Sessions Chicago, IL; April 2, 2003
• 23 Saw J, Steinhubl S R, Berger P B et al.. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.  Circulation. 2003;  108 921-924
• 24 Mitsios J V, Papathanasiou A I, Rodis F I et al.. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.  Circulation. 2004;  109 1335-1338
• 25 Kiemeneij F, Serruys P W, Macaya C et al.. Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial.  J Am Coll Cardiol. 2001;  37 1598-1603
• 26 Serruys P W, van Hout B, Bonnier H et al.. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II).  Lancet. 1998;  352 673-681
• 27 Fischman D L, Leon M B, Baim D S et al.. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.  N Engl J Med. 1994;  331 496-501
• 28 Savage M P, Douglas Jr J S, Fischman D L et al.. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators.  N Engl J Med. 1997;  337 740-747
• 29 Erbel R, Haude M, Hopp H W et al.. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group.  N Engl J Med. 1998;  339 1672-1678
• 30 Nath F C, Muller D W, Ellis S G et al.. Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome.  J Am Coll Cardiol. 1993;  21 622-627
• 31 Schatz R A, Baim D S, Leon M et al.. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study.  Circulation. 1991;  83 148-161
• 32 Leon M B, Baim D S, Popma J J et al.. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.  N Engl J Med. 1998;  339 1665-1671
• 33 Hall P, Nakamura S, Maiello L et al.. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation.  Circulation. 1996;  93 215-222
• 34 Schomig A, Neumann F J, Kastrati A et al.. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.  N Engl J Med. 1996;  334 1084-1089
• 35 Bertrand M E, Legrand V, Boland J et al.. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.  Circulation. 1998;  98 1597-1603
• 36 Kastrati A, Schuhlen H, Hausleiter J et al.. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial.  Circulation. 1997;  96 462-467
• 37 Urban P, Macaya C, Rupprecht H J et al.. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).  Circulation. 1998;  98 2126-2132
• 38 Ito M K, Smith A R, Lee M L. Ticlopidine: a new platelet aggregation inhibitor.  Clin Pharm. 1992;  11 603-617
• 39 Bhatt D L, Bertrand M E, Berger P B et al.. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting.  J Am Coll Cardiol. 2002;  39 9-14
• 40 Mueller C, Roskamm H, Neumann F J et al.. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents.  J Am Coll Cardiol. 2003;  41 969-973
• 41 Mehta S R, Yusuf S, Peters R J et al.. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.  Lancet. 2001;  358 527-533
• 42 Steinhubl S R, Berger P B, Mann III J T et al.. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.  JAMA. 2002;  288 2411-2420
• 43 Vivekananthan D P, Bhatt D L, Chew D P et al.. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention.  Am J Cardiol. 2004;  94 358-360
• 44 Quinn M J, Bhatt D L, Zidar F et al.. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention.  Am J Cardiol. 2004;  93 679-684
• 45 Cannon C P, McCabe C H, Wilcox R G et al.. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.  Circulation. 2000;  102 149-156
• 46 Topol E J, Easton J D, Amarenco P et al.. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial.  Am Heart J. 2000;  139 927-933
• 47 Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes.  Lancet. 2000;  355 337-345
• 48 Second SYMPHONY Investigators . Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes.  Circulation. 2001;  103 1727-1733
• 49 O'Neill W W, Serruys P, Knudtson M et al.. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events.  N Engl J Med. 2000;  342 1316-1324
• 50 Chew D P, Bhatt D L, Sapp S, Topol E J. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.  Circulation. 2001;  103 201-206
• 51 Kastrati A, Mehilli J, Schuhlen H et al.. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.  N Engl J Med. 2004;  350 232-238
• 52 Bhatt D L, Topol E J. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.  Am Heart J. 2004;  148 263-268